Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. . J Crohns Colitis 2026;20:jjag002.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis 2026;20:jjag002.
PMID: 41643213